Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Century Therapeutics, Inc. (IPSC : NSDQ)

• Company Description    Century Therapeutics Inc. is a cell therapy company. It involved in developing induced pluripotent stem cell -derived cell therapies in immuno-oncology. Century Therapeutics Inc. is based in PHILADELPHIA. Number of Employees: 150

• Price / Volume Information    Yesterday's Closing Price: $0.60 Daily Weekly Monthly 20 Day Moving Average: 947,870 shares Shares Outstanding: 86.16 (millions) Market Capitalization: $51.72 (millions) Beta: 1.78 52 Week High: $3.29 52 Week Low: $0.34 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.05% -3.38% 12 Week 10.41% -6.82% Year To Date -40.56% -42.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 25 N 38th Street 11th Floor - PHILADELPHIA,PA 19104 USA ph: 267-817-5790 fax: - investor.relations@centurytx.com http://www.centurytx.com

• General Corporate Information    Officers Brent Pfeiffenberger - Chief Executive Officer Joseph Jimenez - Chairman Morgan Conn - Chief Financial Officer Douglas Carr - Senior Vice President; Finance & Operations Kimberly Blackwell - Director Peer Information Century Therapeutics, Inc. (GSAC) Century Therapeutics, Inc. (CASI) Century Therapeutics, Inc. (ALCD.) Century Therapeutics, Inc. (OMNN) Century Therapeutics, Inc. (CGPI.) Century Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 15673T100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 86.16 Most Recent Split Date: (:1) Beta: 1.78 Market Capitalization: $51.72 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.37 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.26 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.22 Price/Cash Flow: - Price / Sales: 0.45 EPS Growth vs. Year Ago Period: 297.78% vs. Previous Quarter: 306.98% Sales Growth vs. Year Ago Period: 12,667.72% vs. Previous Quarter: 2,515.96% ROE 06/30/25 - - 03/31/25 - -10.71 12/31/24 - -66.88 ROA 06/30/25 - - 03/31/25 - -5.96 12/31/24 - -33.60 Current Ratio 06/30/25 - - 03/31/25 - 11.70 12/31/24 - 1.50 Quick Ratio 06/30/25 - - 03/31/25 - 11.70 12/31/24 - 1.50 Operating Margin 06/30/25 - - 03/31/25 - -19.10 12/31/24 - -1,920.61 Net Margin 06/30/25 - - 03/31/25 - -19.10 12/31/24 - -1,920.61 Pre-Tax Margin 06/30/25 - - 03/31/25 - -17.54 12/31/24 - -1,893.70 Book Value 06/30/25 - - 03/31/25 - 2.79 12/31/24 - 1.90 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©